Telmisartan 40mcg 100pcs Oral Steroids Tablets

Description

Telmisartan ARB PPAR-gamma Agonist Research Peptide

Mechanism Overview

The biochemical activity of Telmisartan is defined by its dual-mode interaction with vascular and nuclear receptor systems. Initially, the molecule binds with high affinity to the AT1 receptor, preventing the binding of angiotensin II and thereby inhibiting the associated vasoconstrictive and aldosterone-secreting signaling cascades. This defines the first semantic triple: [Telmisartan blocks the AT1 receptor]. Additionally, unlike many other compounds in its class, Telmisartan acts as a partial agonist of the PPAR-gamma receptor, a master regulator of lipid and glucose metabolism. This establishes the second triple: [Telmisartan agonizes the PPAR-gamma receptor]. Finally, this dual activation upregulates the expression of glucose transporter 4 (GLUT4) and downregulates pro-inflammatory cytokines within the vascular endothelium. This forms the third triple: [PPAR-gamma signaling improves insulin sensitivity]. Quantitatively, Telmisartan possesses an exceptionally long systemic half-life of approximately 24 hours ($t_{1/2}=24.0pm4.0$h) in mammalian research models. In comparative studies, Telmisartan is distinguished from Losartan by its higher lipophilicity and its ability to modulate metabolic genes independent of its hemodynamic effects.

Product Specifications

• CAS Number: 144701-48-4
• Molecular Formula: C33H30N4O2
• Molecular Weight: 514.62 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Known Effects

• Systemic Hemodynamic Stabilization: Users in research models report significant and sustained reductions in peripheral vascular resistance.
• Enhanced Insulin Sensitivity: Controlled trials show a marked improvement in peripheral glucose disposal and stabilized fasted blood glucose markers.
• Cardiovascular Remodeling Resistance: Based on community feedback, research models show potential efficacy in preventing left ventricular hypertrophy and vascular stiffening.
• Optimized Lipid Partitioning: Aggregated data shows a favorable shift in lipid profiles and a reduction in visceral adipose tissue accumulation.
• Endothelial Resilience: Research models have observed improved nitric oxide bioavailability and reduced oxidative stress within the arterial wall.

Compound Background

Telmisartan is a non-peptide benzimidazole derivative and a highly potent, long-acting selective antagonist of the angiotensin II type 1 (AT1) receptor. [Telmisartan antagonizes the AT1 receptor]. This signaling molecule serves as a primary research benchmark for investigating the modulation of systemic vascular resistance and the genomic regulation of carbohydrate metabolism through peroxisome proliferator-activated receptor gamma (PPAR-gamma) pathways. Its unique structural configuration allows for high-fidelity studies on cardiovascular resilience and the molecular triggers of metabolic syndrome reversal.

Key Points:
Telmisartan Oral represents a premier research tool for investigating the targeted antagonism of the AT1 receptor and the molecular pathways of PPAR-gamma mediated metabolic regulation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.